down arrow

23andMe Holding Co.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US90138Q1085
USD
3.50
-0.1 (-2.78%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.453.57

52 Week

0.476.21
Valuation
Technical
Day's Volume

CASH

41.15 k

Shareholding (Dec 2024)

FII

3.41%

Held by 65 FIIs

DII

71.67%

Held by 16 DIIs

Promoter

9.20%

How big is 23andMe Holding Co.?

22-Jun-2025

As of Jun 18, 23andMe Holding Co. has a market capitalization of 109.62 million, with net sales of 189.89 million and a net profit of -262.12 million over the last four quarters. Shareholder's funds are 188.52 million, and total assets are 395.17 million.

As of Jun 18, 23andMe Holding Co. has a market capitalization of 109.62 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 189.89 million, while the sum of consolidated net profit for the same period is -262.12 million.<BR><BR>As of Mar 24, the shareholder's funds are reported at 188.52 million, and total assets amount to 395.17 million.

Read More

What does 23andMe Holding Co. do?

22-Jun-2025

23andMe Holding Co. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $45 million and a net loss of $99 million as of March 2025. It has a market cap of $109.62 million and no dividend yield.

Overview:<BR>23andMe Holding Co. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 45 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -99 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 109.62 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.45 <BR>Return on Equity: 734.63% <BR>Price to Book: -4.10 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Should I buy, sell or hold 23andMe Holding Co.?

22-Jun-2025

Is 23andMe Holding Co. technically bullish or bearish?

20-Sep-2025

As of July 10, 2025, 23andMe Holding Co. shows a mildly bullish trend supported by daily moving averages and monthly MACD, despite mixed signals from weekly indicators and a concerning long-term performance of -40.67% over the past year compared to the S&P 500's 17.14%.

As of 10 July 2025, the technical trend for 23andMe Holding Co. has changed from mildly bearish to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the monthly MACD also supports this bullish view. However, the weekly MACD and KST remain mildly bearish, suggesting some mixed signals. The Bollinger Bands are sideways on the weekly timeframe, and both the weekly and monthly OBV show a mildly bearish trend. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 1.27% and 10.25% respectively, compared to the S&P 500's returns of 1.05% and 2.33%. However, the longer-term returns are concerning, with a 1-year return of -40.67% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, supported by daily moving averages and monthly MACD, but caution is warranted due to mixed signals from other indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Operating profit has grown by an annual rate -190.83% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -257.20
2

Flat results in Jun 25

3

Risky - Negative EBITDA

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 113 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.31

stock-summary
Return on Equity

352.04%

stock-summary
Price to Book

-2.63

Revenue and Profits:
Net Sales:
25 Million
(Quarterly Results - Jun 2025)
Net Profit:
-24 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.84%
0%
-17.84%
6 Months
-28.86%
0%
-28.86%
1 Year
-3.05%
0%
-3.05%
2 Years
-81.58%
0%
-81.58%
3 Years
9.72%
0%
9.72%
4 Years
-97.71%
0%
-97.71%
5 Years
-98.36%
0%
-98.36%

23andMe Holding Co. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
4.16%
EBIT Growth (5y)
-190.83%
EBIT to Interest (avg)
-257.20
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.45
Sales to Capital Employed (avg)
-1.17
Tax Ratio
0.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
37.42%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.42
EV to EBIT
-0.36
EV to EBITDA
-0.40
EV to Capital Employed
-6.16
EV to Sales
0.37
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-328.10%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bullish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 31 Schemes (15.72%)

Foreign Institutions

Held by 65 Foreign Institutions (3.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -37.13% vs -33.66% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 65.71% vs 33.65% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.40",
          "val2": "40.40",
          "chgp": "-37.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.60",
          "val2": "-66.20",
          "chgp": "59.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.80",
          "val2": "-69.40",
          "chgp": "65.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,208.10%",
          "val2": "-1,780.40%",
          "chgp": "57.23%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -13.52% vs -26.68% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 58.51% vs -81.87% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "189.90",
          "val2": "219.60",
          "chgp": "-13.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-155.90",
          "val2": "-193.50",
          "chgp": "19.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-63.70",
          "val2": "-356.40",
          "chgp": "82.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-235.20",
          "val2": "-566.90",
          "chgp": "58.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-943.70%",
          "val2": "-1,015.10%",
          "chgp": "7.14%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
25.40
40.40
-37.13%
Operating Profit (PBDIT) excl Other Income
-26.60
-66.20
59.82%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-23.80
-69.40
65.71%
Operating Profit Margin (Excl OI)
-1,208.10%
-1,780.40%
57.23%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -37.13% vs -33.66% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 65.71% vs 33.65% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
189.90
219.60
-13.52%
Operating Profit (PBDIT) excl Other Income
-155.90
-193.50
19.43%
Interest
0.00
0.00
Exceptional Items
-63.70
-356.40
82.13%
Consolidate Net Profit
-235.20
-566.90
58.51%
Operating Profit Margin (Excl OI)
-943.70%
-1,015.10%
7.14%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -13.52% vs -26.68% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 58.51% vs -81.87% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About 23andMe Holding Co. stock-summary
stock-summary
23andMe Holding Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."